Century Therapeutics Inc Forecast, price target & analysts
Century Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Century Therapeutics Inc Classifications & Recommendation:
Century Therapeutics Inc Price Target
| Target Price | $6.12 |
| Price | $0.58 |
| Potential |
949.56%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Century Therapeutics Inc 2026 .
The average Century Therapeutics Inc target price is $6.12.
This is
949.56%
register free of charge
$8.40
1,340.58%
register free of charge
$2.02
246.42%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Century Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Century Therapeutics Inc stock has an average upside potential 2026 of
949.56%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.59 | 111.35 |
| 194.20% | 1,589.68% | |
| EBITDA Margin | -1,828.68% | -129.27% |
| 63.47% | 92.93% | |
| Net Margin | -1,920.64% | -8.90% |
| 68.52% | 99.54% |
7 Analysts have issued a sales forecast Century Therapeutics Inc 2025 . The average Century Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Century Therapeutics Inc EBITDA forecast 2025. The average Century Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-121m | 7.46% |
|---|---|---|
| 2025 |
$-144m
19.44%
Unlock
|
|
EBITDA Margin
| 2024 | -1,828.68% | 63.47% |
|---|---|---|
| 2025 |
-129.27%
92.93%
Unlock
|
|
7 Century Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Century Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2024 | -1,920.64% | 68.52% |
|---|---|---|
| 2025 |
-8.90%
99.54%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.61 | -0.11 |
| 30.00% | 93.17% | |
| P/E | negative | |
| EV/Sales | negative |
7 Analysts have issued a Century Therapeutics Inc forecast for earnings per share. The average Century Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Century Therapeutics Inc...
Current Century Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 24 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jan 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
